Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara F. Eichhorst, Manuela A. Bergmann, Thomas Elter, Kathrin Bauer, Gebhart Malchau, Kari G. Rabe, Stephan Stilgenbauer, Hartmut Döhner, Ulrich Jäger, Michael J. Eckart, Georg Hopfinger, Raymonde Busch, Anna Maria Fink, Clemens Martin Wendtner, Kirsten Fischer, Neil Elliot Kay, Michael Hallek

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

In addition to clinical staging, a number of biomarkers predicting overall survival (OS) have been identified in chronic lymphocytic leukemia (CLL). The multiplicity of markers, limited information on their independent prognostic value, and a lack of understanding of how to interpret discordant markers are major barriers to use in routine clinical practice. We therefore performed an analysis of 23 prognostic markers based on prospectively collected data from 1948 CLL patients participating in phase 3 trials of the German CLL Study Group to develop a comprehensive prognostic index. A multi variable Cox regression model identified 8 independent predictors of OS: sex, age, ECOG status, del(17p), del(11q), IGHV mutation status, serum b2-microglobulin, and serum thymidine kinase. Using a weighted grading system, a prognostic index was derived that separated 4 risk categories with 5-year OS ranging from 18.7% to 95.2% and having a C-statistic of 0.75. The index stratified OS within all analyzed subgroups, including all Rai/Binet stages. The validity of the index was externally confirmed in a series of 676 newly diagnosed CLL patients from Mayo Clinic. Using this multistep process including external validation, we developed a comprehensive prognostic index with high discriminatory power and prognostic significance on the individual patient level.

Original languageEnglish (US)
Pages (from-to)49-62
Number of pages14
JournalBlood
Volume124
Issue number1
DOIs
StatePublished - Jul 3 2014

Fingerprint

Thymidine Kinase
Biomarkers
B-Cell Chronic Lymphocytic Leukemia
Statistics
Survival
Serum
Proportional Hazards Models
Mutation

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Pflug, N., Bahlo, J., Shanafelt, T. D., Eichhorst, B. F., Bergmann, M. A., Elter, T., ... Hallek, M. (2014). Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood, 124(1), 49-62. https://doi.org/10.1182/blood-2014-02-556399

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. / Pflug, Natali; Bahlo, Jasmin; Shanafelt, Tait D.; Eichhorst, Barbara F.; Bergmann, Manuela A.; Elter, Thomas; Bauer, Kathrin; Malchau, Gebhart; Rabe, Kari G.; Stilgenbauer, Stephan; Döhner, Hartmut; Jäger, Ulrich; Eckart, Michael J.; Hopfinger, Georg; Busch, Raymonde; Fink, Anna Maria; Wendtner, Clemens Martin; Fischer, Kirsten; Kay, Neil Elliot; Hallek, Michael.

In: Blood, Vol. 124, No. 1, 03.07.2014, p. 49-62.

Research output: Contribution to journalArticle

Pflug, N, Bahlo, J, Shanafelt, TD, Eichhorst, BF, Bergmann, MA, Elter, T, Bauer, K, Malchau, G, Rabe, KG, Stilgenbauer, S, Döhner, H, Jäger, U, Eckart, MJ, Hopfinger, G, Busch, R, Fink, AM, Wendtner, CM, Fischer, K, Kay, NE & Hallek, M 2014, 'Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia', Blood, vol. 124, no. 1, pp. 49-62. https://doi.org/10.1182/blood-2014-02-556399
Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014 Jul 3;124(1):49-62. https://doi.org/10.1182/blood-2014-02-556399
Pflug, Natali ; Bahlo, Jasmin ; Shanafelt, Tait D. ; Eichhorst, Barbara F. ; Bergmann, Manuela A. ; Elter, Thomas ; Bauer, Kathrin ; Malchau, Gebhart ; Rabe, Kari G. ; Stilgenbauer, Stephan ; Döhner, Hartmut ; Jäger, Ulrich ; Eckart, Michael J. ; Hopfinger, Georg ; Busch, Raymonde ; Fink, Anna Maria ; Wendtner, Clemens Martin ; Fischer, Kirsten ; Kay, Neil Elliot ; Hallek, Michael. / Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. In: Blood. 2014 ; Vol. 124, No. 1. pp. 49-62.
@article{8981a9d31f614431b03569672a49c005,
title = "Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia",
abstract = "In addition to clinical staging, a number of biomarkers predicting overall survival (OS) have been identified in chronic lymphocytic leukemia (CLL). The multiplicity of markers, limited information on their independent prognostic value, and a lack of understanding of how to interpret discordant markers are major barriers to use in routine clinical practice. We therefore performed an analysis of 23 prognostic markers based on prospectively collected data from 1948 CLL patients participating in phase 3 trials of the German CLL Study Group to develop a comprehensive prognostic index. A multi variable Cox regression model identified 8 independent predictors of OS: sex, age, ECOG status, del(17p), del(11q), IGHV mutation status, serum b2-microglobulin, and serum thymidine kinase. Using a weighted grading system, a prognostic index was derived that separated 4 risk categories with 5-year OS ranging from 18.7{\%} to 95.2{\%} and having a C-statistic of 0.75. The index stratified OS within all analyzed subgroups, including all Rai/Binet stages. The validity of the index was externally confirmed in a series of 676 newly diagnosed CLL patients from Mayo Clinic. Using this multistep process including external validation, we developed a comprehensive prognostic index with high discriminatory power and prognostic significance on the individual patient level.",
author = "Natali Pflug and Jasmin Bahlo and Shanafelt, {Tait D.} and Eichhorst, {Barbara F.} and Bergmann, {Manuela A.} and Thomas Elter and Kathrin Bauer and Gebhart Malchau and Rabe, {Kari G.} and Stephan Stilgenbauer and Hartmut D{\"o}hner and Ulrich J{\"a}ger and Eckart, {Michael J.} and Georg Hopfinger and Raymonde Busch and Fink, {Anna Maria} and Wendtner, {Clemens Martin} and Kirsten Fischer and Kay, {Neil Elliot} and Michael Hallek",
year = "2014",
month = "7",
day = "3",
doi = "10.1182/blood-2014-02-556399",
language = "English (US)",
volume = "124",
pages = "49--62",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

AU - Pflug, Natali

AU - Bahlo, Jasmin

AU - Shanafelt, Tait D.

AU - Eichhorst, Barbara F.

AU - Bergmann, Manuela A.

AU - Elter, Thomas

AU - Bauer, Kathrin

AU - Malchau, Gebhart

AU - Rabe, Kari G.

AU - Stilgenbauer, Stephan

AU - Döhner, Hartmut

AU - Jäger, Ulrich

AU - Eckart, Michael J.

AU - Hopfinger, Georg

AU - Busch, Raymonde

AU - Fink, Anna Maria

AU - Wendtner, Clemens Martin

AU - Fischer, Kirsten

AU - Kay, Neil Elliot

AU - Hallek, Michael

PY - 2014/7/3

Y1 - 2014/7/3

N2 - In addition to clinical staging, a number of biomarkers predicting overall survival (OS) have been identified in chronic lymphocytic leukemia (CLL). The multiplicity of markers, limited information on their independent prognostic value, and a lack of understanding of how to interpret discordant markers are major barriers to use in routine clinical practice. We therefore performed an analysis of 23 prognostic markers based on prospectively collected data from 1948 CLL patients participating in phase 3 trials of the German CLL Study Group to develop a comprehensive prognostic index. A multi variable Cox regression model identified 8 independent predictors of OS: sex, age, ECOG status, del(17p), del(11q), IGHV mutation status, serum b2-microglobulin, and serum thymidine kinase. Using a weighted grading system, a prognostic index was derived that separated 4 risk categories with 5-year OS ranging from 18.7% to 95.2% and having a C-statistic of 0.75. The index stratified OS within all analyzed subgroups, including all Rai/Binet stages. The validity of the index was externally confirmed in a series of 676 newly diagnosed CLL patients from Mayo Clinic. Using this multistep process including external validation, we developed a comprehensive prognostic index with high discriminatory power and prognostic significance on the individual patient level.

AB - In addition to clinical staging, a number of biomarkers predicting overall survival (OS) have been identified in chronic lymphocytic leukemia (CLL). The multiplicity of markers, limited information on their independent prognostic value, and a lack of understanding of how to interpret discordant markers are major barriers to use in routine clinical practice. We therefore performed an analysis of 23 prognostic markers based on prospectively collected data from 1948 CLL patients participating in phase 3 trials of the German CLL Study Group to develop a comprehensive prognostic index. A multi variable Cox regression model identified 8 independent predictors of OS: sex, age, ECOG status, del(17p), del(11q), IGHV mutation status, serum b2-microglobulin, and serum thymidine kinase. Using a weighted grading system, a prognostic index was derived that separated 4 risk categories with 5-year OS ranging from 18.7% to 95.2% and having a C-statistic of 0.75. The index stratified OS within all analyzed subgroups, including all Rai/Binet stages. The validity of the index was externally confirmed in a series of 676 newly diagnosed CLL patients from Mayo Clinic. Using this multistep process including external validation, we developed a comprehensive prognostic index with high discriminatory power and prognostic significance on the individual patient level.

UR - http://www.scopus.com/inward/record.url?scp=84903971364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903971364&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-02-556399

DO - 10.1182/blood-2014-02-556399

M3 - Article

C2 - 24797299

AN - SCOPUS:84903971364

VL - 124

SP - 49

EP - 62

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -